Eli Lilly and Company

Theodore Goodson, Jr

David Kent Herron

Michael Robert Wiley

Jason Scott Sawyer

Gerald Floyd Smith

John Joseph Masters

Ying Kwong Yee

David Mendel

Douglas Wade Beight

Jeffry Bernard Franciskovich

Anne Louise Tebbe

Steven E Hall

James Howard Wikel

Robert T Shuman

Valentine Joseph Klimkowski

Jennifer Marie Tinsley

Leonard Crayton Weir

Trelia Joyce Craft

Guy Milot

Jeffrey Alan Kyle

Sajan Joseph

Wayne A Spitzer

Marta Maria Pi&ntilde;eiro-N&uacute;&ntilde;ez

Richard Waltz Harper

Nancy G Bollinger

Carl Penman Denny

Leander Merritt

Andrew Michael Ratz

Angela Lynn Marquart

Marta Maria Pi&ntilde;eiro-Nu&ntilde;ez

Stjepan P Kukolja

John E Toth

William Thomas McMillen

Edward C R Smith

Alexander Glenn Godfrey

Shawn Christopher Miller

Hong-Yu Li

Steven R Lammert

Mary Margaret Mader

Marta Maria Pineiro-Nunez

Jonathan Michael Yingling

Salvatore Donato Lepore

Todd Vincent Decollo

Guy Milet

Arindam Chatterjee

Ankush Baburao Argade

Marta Maria Pinelro-Núnez

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a). 

Aromatic ether derivatives useful as thrombin inhibitors

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Antithrombotic aromatic ethers

The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.

Mixed lineage kinase modulators

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Aromatic amides

Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S

Pyrrole derivatives as pharmaceutical agents

Antithrombotic amides

This application relates to heteroaromatic amides (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Heteroroaromatic amides as inhibitor of factor Xa

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Antithrombotic agents

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermidates thereof.

Growing community of inventors

Indianapolis, IN, United States of America

Theodore Goodson, Jr